ThisCART19A

Phase 1Cell therapy

FFundamenta Therapeutics, Ltd.

ThisCART19A is one of 141 small molecule programs targeting Hemolytic Anemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

140

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hemolytic AnemiaActive, not recruiting

LymphomaActive, not recruiting

LeukemiaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

Hemolytic AnemiaPhase 1

Active, not recruiting

LymphomaPhase 1

Active, not recruiting

LeukemiaPhase 1

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Oncaspar

SServier

Preclinical

15 2

Zofran

Novartis

Preclinical

2 3

ThisCART19A

FFundamenta Therapeutics, Ltd.

Phase 1

2 4

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 5

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 6

Decadron

QQuince Therapeutics S.p.A.

PEG-Intron

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 10

R-CHOP

IIncyte Biosciences Japan GK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Active, not recruiting

Acute Lymphoblastic Leukemia

NCT07074496

Clinical

Trials by Indication[1]

Lymphoma2 trials

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Unknown status·—·Phase 1/2·NCT05776407·12 enrolled

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Unknown status·ZZhengzhou University·Phase 1·NCT05535673·15 enrolled

Efficacy2 trials

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL

Unknown status·ZZhejiang University·Phase 1·NCT05350852·16 enrolled

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL

Completed·ZZhejiang University·Phase 1·NCT05350787·10 enrolled

Leukemia1 trial

Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia

Unknown status·HHe Huang·Phase 1·NCT05340829·18 enrolled

Hemolytic Anemia1 trial

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT06212154·13 enrolled

Acute Lymphoblastic Leukemia1 trial

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Active, not recruiting·TThe First Affiliated Hospital of Soochow University·Phase 1·NCT07074496·20 enrolled

3 more indications

B-cell Malignancies1 trial

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Unknown status·HHenan Cancer Hospital·Phase 1·NCT05640713·12 enrolled

B-cell acute lymphoblastic leukemia1 trial

Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

Unknown status·FFundamenta Therapeutics, Ltd.·Phase 1·NCT05576181·19 enrolled

Safety and Efficacy1 trial

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Unknown status·ZZhejiang University·Phase 1·NCT05349266·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for ThisCART19A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ThisCART19A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ThisCART19A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundamenta Therapeutics, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: FFundamenta Therapeutics, Ltd.

ThisCART19A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Lymphoma2 trials

Efficacy2 trials

Leukemia1 trial

Hemolytic Anemia1 trial

Acute Lymphoblastic Leukemia1 trial

B-cell Malignancies1 trial

B-cell acute lymphoblastic leukemia1 trial

Safety and Efficacy1 trial

References

Drug Info

Quick Facts

Related News